AR102562A1 - Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina - Google Patents
Métodos para tratar la enfermedad de huntington usando composiciones de cisteaminaInfo
- Publication number
- AR102562A1 AR102562A1 ARP150103610A ARP150103610A AR102562A1 AR 102562 A1 AR102562 A1 AR 102562A1 AR P150103610 A ARP150103610 A AR P150103610A AR P150103610 A ARP150103610 A AR P150103610A AR 102562 A1 AR102562 A1 AR 102562A1
- Authority
- AR
- Argentina
- Prior art keywords
- bdnf
- disease
- compositions
- methods
- cisteamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para el tratamiento de enfermedades neurodegenerativas, tales como la Enfermedad de Huntington, usando composiciones que comprenden cisteamina o cistamina o sales o derivados de las mismas. Reivindicación 11: El método de acuerdo con la reivindicación 10, caracterizado porque la terapia adjunta se selecciona del grupo que consiste en una terapia a base de antipsicóticos, de antidepresivos, de inhibidores de los transportadores de monoaminas vesiculares (VMAT), tales como la tetrabenazina, de inhibidores de la dopamina, de laquinimod, de inmunomoduladores del SNC, de factores neuroprotectores, del BDNF, de agentes útiles para incrementar la actividad del BDNF, de ampaquinas, de moduladores positivos de los receptores del glutamato del tipo del AMPA o de activadores de los receptores del BDNF del tipo de TrkB, y una terapia génica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075536P | 2014-11-05 | 2014-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102562A1 true AR102562A1 (es) | 2017-03-08 |
Family
ID=55909803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103610A AR102562A1 (es) | 2014-11-05 | 2015-11-05 | Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160128954A1 (es) |
| EP (1) | EP3215222A4 (es) |
| JP (1) | JP2017533967A (es) |
| CN (1) | CN107106875A (es) |
| AR (1) | AR102562A1 (es) |
| AU (1) | AU2015343060A1 (es) |
| BR (1) | BR112017009448A2 (es) |
| CA (1) | CA2966879A1 (es) |
| TW (1) | TW201618760A (es) |
| WO (1) | WO2016073716A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117599029A (zh) | 2016-03-17 | 2024-02-27 | 硫创治疗公司 | 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物 |
| EP3684418A4 (en) * | 2017-09-20 | 2021-06-16 | Thiogenesis Therapeutics, Inc. | TREATMENT METHODS FOR CYSTEAMINE SENSITIVE CONDITIONS |
| EP3946298A4 (en) * | 2019-03-26 | 2023-01-25 | The Regents of the University of California | SUBSTITUTED AMINO-THIOL AND AMINODISULFIDE COMPOUNDS AND THEIR USES |
| BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049307T2 (hu) * | 2006-01-27 | 2020-09-28 | Univ California | Bélben oldódó bevonattal ellátott ciszteamin-bitartrát és cisztamin |
| US20120309785A1 (en) * | 2010-12-03 | 2012-12-06 | Bill Piu Chan | Use of Cysteamine in Treating Parkinson's Disease |
| CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
-
2015
- 2015-11-04 TW TW104136399A patent/TW201618760A/zh unknown
- 2015-11-05 JP JP2017544287A patent/JP2017533967A/ja active Pending
- 2015-11-05 CN CN201580071440.9A patent/CN107106875A/zh active Pending
- 2015-11-05 AU AU2015343060A patent/AU2015343060A1/en not_active Abandoned
- 2015-11-05 US US14/933,529 patent/US20160128954A1/en not_active Abandoned
- 2015-11-05 WO PCT/US2015/059239 patent/WO2016073716A1/en active Application Filing
- 2015-11-05 EP EP15857339.4A patent/EP3215222A4/en not_active Withdrawn
- 2015-11-05 AR ARP150103610A patent/AR102562A1/es unknown
- 2015-11-05 BR BR112017009448A patent/BR112017009448A2/pt not_active Application Discontinuation
- 2015-11-05 CA CA2966879A patent/CA2966879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160128954A1 (en) | 2016-05-12 |
| CN107106875A (zh) | 2017-08-29 |
| WO2016073716A1 (en) | 2016-05-12 |
| BR112017009448A2 (pt) | 2017-12-19 |
| JP2017533967A (ja) | 2017-11-16 |
| TW201618760A (zh) | 2016-06-01 |
| EP3215222A4 (en) | 2018-06-13 |
| AU2015343060A1 (en) | 2017-05-25 |
| CA2966879A1 (en) | 2016-05-12 |
| EP3215222A1 (en) | 2017-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO2017000438A2 (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| CO2017000222A2 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP17035750A (es) | Composición de liberación modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| AR102562A1 (es) | Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| UY36123A (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |